GLP-1 Peptides: The Research Behind a Major Metabolic Drug Class

GLP-1 (glucagon-like peptide-1) receptor agonists are the active molecule behind several FDA-approved pharmaceutical products, and the underlying mechanism mimics a hormone naturally produced in the gut.

The clinical trial literature is substantial, and this article summarizes the published research and trial data.

What GLP-1 Does, Mechanistically

GLP-1 is released after food intake. It signals the pancreas to produce insulin, slows gastric emptying, and acts on satiety signaling in the brain. Research shows that people with obesity and type-2 diabetes often have a blunted endogenous GLP-1 response, which is part of the mechanistic rationale for this drug class.

Semaglutide vs Tirzepatide

• •Semaglutide is a single GLP-1 receptor agonist. Long half-life, once-weekly dosing.
• •Tirzepatide is a dual GIP/GLP-1 agonist, it hits two pathways at once, which is why head-to-head trials show greater average weight loss.

What the Research Shows

In the STEP and SURMOUNT trials, participants lost 15 to 22% of body weight over 68 to 72 weeks. That's territory previously only reached by bariatric surgery.

But peptides are not magic:

• •Muscle loss is real if protein intake and resistance training are neglected
• •Side effects (nausea, fatigue) are dose-dependent
• •Weight regain happens if the peptide is stopped without lifestyle change

Summary of the Research

Trial data consistently shows the largest and most durable outcomes in study arms that combined GLP-1 receptor agonist administration with resistance training, adequate protein intake, and long-term maintenance planning, rather than administration in isolation.

How GLP-1 Works in More Detail

When food enters the small intestine, L-cells in the gut wall release GLP-1 in proportion to the macronutrient load. GLP-1 then acts on multiple tissues simultaneously:

• •Pancreatic beta cells, glucose-dependent insulin secretion (it only triggers insulin when glucose is elevated, which is why hypoglycemia is rare)
• •Pancreatic alpha cells, suppression of glucagon
• •Stomach, slowed gastric emptying (longer-lasting fullness)
• •Hypothalamus, appetite suppression via the arcuate nucleus
• •Reward centers, reduced hedonic eating drive ("food noise" reduction)

The combination of these effects is why GLP-1 receptor agonists produce weight loss magnitudes that are unprecedented in pharmacology.

Why Long-Acting Analogs Were a Breakthrough

Native GLP-1 has a half-life of roughly two minutes, it is degraded almost immediately by the enzyme DPP-4. The first-generation drugs (exenatide, liraglutide) had short half-lives and required frequent dosing. The breakthrough came with structural modifications that resist DPP-4 cleavage and bind plasma albumin via fatty-acid side chains. Semaglutide has a half-life of roughly seven days. Tirzepatide has a half-life of around five days. Once-weekly dosing changed the practical reality of the class.

STEP and SURMOUNT, The Trials That Changed the Field

The STEP-1 trial (NEJM, 2021) tested semaglutide 2.4 mg weekly in adults with obesity without diabetes (1). Mean weight loss at 68 weeks: −14.9% vs −2.4% placebo. The SURMOUNT-1 trial (NEJM, 2022) tested tirzepatide 15 mg weekly in the same population (2). Mean weight loss at 72 weeks: −20.9%. The Phase II retatrutide data (Jastreboff et al., NEJM 2023) reached −24.2% at 48 weeks with a triple GIP/GLP-1/glucagon mechanism (3). These are weight-loss magnitudes previously achievable only with bariatric surgery.

The Cardiovascular Story

GLP-1 receptor agonists have a class effect on cardiovascular outcomes. SUSTAIN-6 (semaglutide) cut major adverse cardiovascular events by 26% in type 2 diabetes (4). SELECT (NEJM 2023) extended that finding to non-diabetic patients with obesity and prior cardiovascular disease, cutting MACE by 20% (5). The mechanism is multifactorial: weight loss, blood pressure reduction, anti-inflammatory effects, and direct vascular signaling.

Side Effects and Tolerability

Most side effects are gastrointestinal and dose-dependent:

• •Nausea, vomiting, diarrhea, 30–50% of subjects in trials, mostly transient with slow titration
• •Constipation, common, often persistent
• •Gallbladder events, small but consistent signal across trials
• •Pancreatitis, no causal link in pooled analyses despite early concerns
• •Lean mass loss, roughly 25–40% of weight lost is lean mass without resistance training and adequate protein

The lean mass issue is the most under-discussed. Without protein and resistance training, GLP-1-driven weight loss compromises functional capacity and metabolic rate.

Lean Mass Preservation in Trial Design

Published research consistently identifies protein intake and resistance training as key variables for preserving lean mass in study populations undergoing GLP-1-driven weight loss. Trial arms combining structured resistance training and higher protein intake with GLP-1 receptor agonist administration showed preserved lean mass and better long-term body-composition outcomes than arms relying on appetite suppression alone.

The Discontinuation Effect

The STEP-4 trial showed that trial subjects who discontinued semaglutide regained roughly two-thirds of the weight lost within a year (6). This trial result establishes that GLP-1 receptor agonists function pharmacologically as an ongoing intervention rather than a finite course, with research literature describing distinct active-phase and maintenance-phase dosing arms in long-term study designs.

Summary

GLP-1 receptor agonists have produced the largest weight-loss and cardiometabolic effects recorded in modern pharmacological trials. The literature also documents that outcomes vary substantially based on study-arm design, protein intake, resistance training, and discontinuation planning are recurring variables that differentiate durable outcomes from short-lived ones with lean-mass loss.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. PMID: 33567185.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. PMID: 35658024.
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. PMID: 37366315.
4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. PMID: 27633186.
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. PMID: 37952131.
6. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021 Apr 13;325(14):1414-1425. PMID: 33755728.